Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models

Devalingam Mahalingam, Jennifer S. Carew, Claudia M. Espitia, Robbert H. Cool, Francis J. Giles, Steven De Jong, Steffan T. Nawrocki*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis that may be a promising agent in cancer therapy due to its selectivity toward tumor cells. However, many cancer cells are resistant to TRAIL due to defects in apoptosis signaling or activation of survival pathways. We hypothesized that a disruption of pro-survival signaling cascades with the multi-tyrosine kinase inhibitor sunitinib and would be an effective strategy to enhance TRAIL-mediated apoptosis. Here we demonstrate that sunitinib significantly augments the anticancer activity of TRAIL in models of colon cancer. The therapeutic benefit of the TRAIL/sunitinib combination was associated with increased apoptosis marked by enhanced caspase-3 cleavage and DNA fragmentation. Overexpression of the anti-apoptotic factor B-cell lymphoma 2 (BCL-2) in HCT116 cells reduced TRAIL/sunitinib-mediated apoptosis, further supporting that sunitinib enhances the anticancer activity of TRAIL via augmented apoptosis. Analysis of pro-survival factors identified that the combination of TRAIL and sunitinib significantly downregulated the anti-apoptotic protein X-linked inhibitor of apoptosis protein (XIAP) through a c-Jun N-terminal kinase (JNK)-mediated mechanism. Short hairpin RNA (shRNA)-mediated knockdown of JNK confirmed its key role in the regulation of sensitivity to this combination as cells with suppressed JNK expression exhibited significantly reduced TRAIL/sunitinib-mediated apoptosis. Importantly, the therapeutic benefit of the TRAIL/sunitinib combination was validated in the HCT116-Luc and HCT15 colon cancer xenograft models, which both demonstrated significant anti-tumor activity in response to combination treatment. Collectively, our data demonstrate that sunitinib enhances TRAIL-mediated apoptosis by heightened JNK activation, diminished XIAP levels, and augmented apoptosis.

Original languageEnglish (US)
Article number895
Issue number7
StatePublished - Jul 2019


  • Apoptosis
  • Colon cancer
  • Sunitinib
  • XIAP

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Heightened JNK activation and reduced XIAP levels promote TRAIL and sunitinib-mediated apoptosis in colon cancer models'. Together they form a unique fingerprint.

Cite this